Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04514367 · ClinicalTrials.gov registry record · Phase 2
An Open Label Study of ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease
A Phase 2 study, sponsored by Annexon.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT04514367: Completed Phase 2 study, sponsored by Annexon.
NCT04514367 is a Phase 2 study that has completed, run by Annexon. The registered enrollment target is 28 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04514367, a Phase 2 study, has completed, sponsored by Annexon.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
This study is a multi-center, open-label study of intravenous (IV) ANX005 in subjects with, or at risk for, manifest Huntington's Disease (HD).
Primary Outcome
An adverse event (AE) was defined as any untoward medical occurrence that developed or worsened in severity during the conduct of a clinical study and does not necessarily have a causal relationship to study drug. Serious AEs (SAEs) included death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or, a congenital anomaly or birth defect, or an important medical event that jeopardized the participant and required me
Interventions
- DRUG ANX005
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2020-08-17 |
| Est. Completion | 2022-01-28 |
| Phase | Phase 2 |
What the finished NCT04514367 record still lists
NCT04514367 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower).
The record links to 0 conditions, and to 1 intervention - of which ANX005 is the first listed.
NCT04514367 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04514367 about?
NCT04514367 is a clinical study titled "An Open Label Study of ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease". This study is a multi-center, open-label study of intravenous (IV) ANX005 in subjects with, or at risk for, manifest Huntington's Disease (HD).
What is the current status of trial NCT04514367?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2020-08-17. Estimated completion is 2022-01-28.
What interventions are being tested in trial NCT04514367?
The interventions under investigation include: ANX005 (DRUG).
Who is sponsoring clinical trial NCT04514367?
This trial is sponsored by Annexon, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04514367's enrollment target sits among peer trials
28 1677th of 2000 higher than 304 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI